SynthesisFrontiers in immunology2023
The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis.Frontiers in immunology · 2024Pooled it
- Trial
- Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.Annals of surgical oncology · 2024Trial
- Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Clinical and translational radiation oncology · 2027Review
- Article
- Review
- The Impact of Tumor Volume Change Rate During Neoadjuvant Chemoradiotherapy-immunotherapy and of the Timing to Surgery on Prognosis in Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Study.Journal of gastrointestinal cancer · 2026Article
- Article
- CD172aBMC gastroenterology · 2026Article
- Comparison of survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced esophageal squamous cell carcinoma.JTCVS open · 2026Article
- Targeting intratumoral Streptococcus mitis suppresses the progression of esophageal squamous cell carcinoma.Science China. Life sciences · 2026Article
- Unlocking the potential of radiomics in predicting the response of neoadjuvant immunochemotherapy for operable locally advanced esophageal squamous cell carcinoma: a narrative review.Journal of thoracic disease · 2026Review
- Treatment patterns and clinical outcomes of neoadjuvant chemoimmunotherapy for patients with resected oesophageal squamous cell carcinoma: a Chinese multicentre retrospective study.Therapeutic advances in medical oncology · 2026Article
- A pathological classification for predicting recurrence and guiding adjuvant therapy in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: a two-center cohort study.Frontiers in oncology · 2026Article
- Efficacy and safety of secondary induction radiotherapy in locally advanced resectable esophageal squamous cell carcinoma with poor responses to neoadjuvant immunochemotherapy: a retrospective study.Frontiers in immunology · 2026Article
- Preoperative risk stratification for pulmonary complications after neoadjuvant therapy and esophagectomy in locally advanced esophageal squamous cell carcinoma: a retrospective cohort study.Frontiers in oncology · 2026Article
- Bibliometric examination of neoadjuvant immunotherapy in esophageal cancer: insights, trends, collaborative networks, and prospective directions.Journal of thoracic disease · 2025Article
- Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.Scientific reports · 2025Article
- Article
- Neoadjuvant arterial infusion chemotherapy combined with immunotherapy in treating locally advanced lower esophageal and esophagogastric junction cancer.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aimed to explore the efficacy and safety of neoadjuvant immunotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Background: Several studies have reported the outcomes of neoadjuvant immunotherapy in patients with ESCC. However, phase 3 randomized controlled trials (RCTs) with long-term outcomes and the comparison of different therapeutic strategies are lacking. Methods: Studies involving patients with advanced ESCC treated with preoperative neoadjuvant immune checkpoint inhibitors (ICIs) were searched through PubMed, Embase, and Cochrane Library up to July 1, 2022. The outcomes were presented as proportions and pooled respectively by fixed or random effect model depending on the heterogeneity between studies. All analyses were performed using the R packages meta 5.5-0 and meta-for 3.4-0. Results: Thirty trials involving 1406 patients were included in the meta-analysis. The pooled pathological complete response (pCR) rate for neoadjuvant immunotherapy was 0.30 (95% confidence interval [CI]: 0.26-0.33). The pCR rate of neoadjuvant immunotherapy combined with chemoradiotherapy (nICRT) was significantly higher than that of neoadjuvant immunotherapy combined with chemotherapy (nICT) (nICRT: 0.48, 95% CI: 0.31-0.65; nICT: 0.29, 95% CI: 0.26-0.33; Conclusion: Neoadjuvant immunotherapy has good efficacy and safety profiles in patients with locally advanced ESCC. Additional RCTs with long-term survival data are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.